A month after the US announcement, Kluge explained to EU lawmakers in Brussels that the organisation is currently in a “stop the bleeding” phase – the first of three. “Meaning very ...
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...
PARIS, France I March 28, 2025 I The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for ...
Despite advances in anticoagulant therapies, bleeding remains a critical concern.Traditionally, the definition of major ...
Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg ...
In the first phase, data on consecutive UGI bleeders were collected at three hospitals prospectively and retrospectively at the fourth. UGI bleeding was defined as hematemesis, coffee-ground vomit ...
Despite this prevalence, few studies have examined the issue nor have they explained the link between abnormal uterine bleeding during the menopause transition phase and fatigue or decreased ...
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...
A month after the US announcement, Kluge explained to EU lawmakers in Brussels that the organisation is currently in a “stop the bleeding” phase – the first of three. “Meaning very, very brutal cost ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback